Stefan Kaspers

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

David Fitchett, Silvio E. Inzucchi, Christopher P. Cannon et al. · Circulation · 2019 · 358 citations · Full text

Medicine, Cardiology, Pharmacology +17

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Julio Rosenstock, Jan Marquard, Lori M. Laffel et al. · Diabetes Care · 2018 · 357 citations

Medicine, Pharmacology, Pharmacotherapy +17

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

Bruce A. Perkins, David Z.I. Cherney, Helen Partridge et al. · Diabetes Care · 2014 · 228 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials

Sven Köhler, Cordula Zeller, Hristo Iliev et al. · Advances in Therapy · 2017 · 192 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

David Z.I. Cherney, Søren S. Lund, Bruce A. Perkins et al. · Diabetologia · 2016 · 172 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14